Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement

BIOXYTRAN, INC

Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.
CEO David Platt says deal marks transition from development-stage to recurring commercial revenue while preserving IP ownership.
Volume-based marketplace exclusivity possible if defined purchase thresholds are met, per agreement terms.
Initial commercial shipments expected after completion of standard launch preparations; manufacturing by Bioxytran's OEM.
Bioxytran retains full IP; deal applies only to non-pharmaceutical dietary products, preserving pharma/antiviral programs.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIOXYTRAN, INC entered into Distribution Agreement with Khoury Medical LTD (effective 2026-02-10).

Action: entry
Agreement: supply
Counterparty: Khoury Medical LTD
Effective: 2026-02-10

Exact text from the filing

On February 10, 2026, Bioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

BIOXYTRAN, INC filing history →

Source: SEC EDGAR

accession 0001493152-26-006891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.